Skip to main content
Clinical Trials/NCT06601621
NCT06601621
Recruiting
Not Applicable

Study on the Impact of Electroacupuncture Combined With Self-Acupressure on the Quality of Life of Patients With Early-Stage Breast Cancer Undergoing Chemotherapy

Jiuda Zhao1 site in 1 country192 target enrollmentOctober 19, 2024

Overview

Phase
Not Applicable
Intervention
electroacupuncture+ self-acupressure
Conditions
Electroacupuncture
Sponsor
Jiuda Zhao
Enrollment
192
Locations
1
Primary Endpoint
Differences in quality of life during the overall stage
Status
Recruiting
Last Updated
2 months ago

Overview

Brief Summary

This randomized controlled clinical trial aims to evaluate the effect of electroacupuncture combined with self-acupressure on the quality of life of early-stage breast cancer patients receiving chemotherapy.

Detailed Description

This study is a parallel-group, blinded (participant, evaluator, and statisticians), randomized controlled trial to investigate the effect of electroacupuncture combined with self-acupressure on the quality of life of early-stage breast cancer patients receiving chemotherapy. Patients in each group will receive electroacupuncture or sham electroacupuncture during the first week of the chemotherapy cycle. They will receive self-acupressure or sham acupressure during the second and third weeks of the chemotherapy cycle. Participants will be asked to complete the EQ-5D-5L and FACT-B scales. Primary and secondary outcomes will be assessed.

Registry
clinicaltrials.gov
Start Date
October 19, 2024
End Date
April 30, 2026
Last Updated
2 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Jiuda Zhao
Responsible Party
Sponsor Investigator
Principal Investigator

Jiuda Zhao

Breast Disease Diagnosis and Treatment Center

Affiliated Hospital of Qinghai University

Eligibility Criteria

Inclusion Criteria

  • Aged 18 years or older and aged 75 years or younger, inclusive. with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;
  • Patients who have not received prior chemotherapy and are scheduled to receive at least 4 cycles of adjuvant or neoadjuvant chemotherapy or combination targeted therapy;
  • Normal organ function with platelets ≥ 100\*10\^9/ L, hemoglobin ≥ 90 g/L, serum creatinine ≤ 1.5 mg/dl (133 mmol/L), or creatinine clearance ≥ 60 ml/min, total bilirubin ≤ 1.5 times the upper limit of normal (ULN), alanine aminotransferase ≤ 2.5 times ULN, and aspartate aminotransferase ≤ 2.5 times ULN;
  • Premenopausal women need appropriate contraception;
  • Ability to understand the study well and complete the study questionnaire.

Exclusion Criteria

  • Patients with needle phobia or allergy to stainless steel needles; and
  • Current diagnosis of mental illness (e.g., major depression, obsessive-compulsive disorder, or schizophrenia);
  • History of autoimmune diseases, blood disorders, or organ transplantation, or long-term use of hormones or immunosuppressants;
  • Comorbid bleeding disorders or thyroid dysfunction;
  • Implantation of a pacemaker; pregnancy or breastfeeding;
  • A plan for adjuvant radiotherapy in the upcoming chemotherapy cycle;
  • Current active infection;
  • Acupuncture treatment within the last four weeks;
  • Patients who are allergic to the drugs used;
  • Use of other Traditional Chinese Medicine (TCM) techniques such as Chinese herbs in the next chemotherapy cycle.

Arms & Interventions

True electroacupuncture + True self-acupressure

Participants will receive two electroacupuncture treatments during the first week of the chemotherapy cycle. The acupuncturist will insert needles into the acupoints and manipulate the needles until"de qi"sensation is achieved and reported by the participants. Electrical stimulation will be delivered for 30 minutes at alternating frequencies of 2/10Hz. Participants will do acupressure daily during the second week of the chemotherapy cycle (two weeks for one chemotherapy cycle) or the second and third weeks (three weeks for one chemotherapy cycle). participants performed true self-acupressure, pressing each acupoint with their thumb to achieve "deqi" for three minutes.

Intervention: electroacupuncture+ self-acupressure

Sham electroacupuncture + Sham self-acupressure

The sham acupuncture is the use of minimally invasive shallow needle insertion using thin and short needles at body locations not recognized as true acupuncture points and are deemed to not belong to traditional Chinese meridians and have no therapeutic value. Participants will receive minimal acupuncture treatment without electrical stimulation at the same time as the intervention group. Care was taken to avoid "de qi" sensation. Sham self-acupressure: Administered non-acupressure points 1 to 3cm away from the true acupressure points used in the experimental group and away from known meridians. The frequency, course duration, and overall treatment time will be the same as those in the true self-administered shiatsu group. The applied pressure does not cause a feeling of "deqi".

Intervention: sham electroacupuncture + sham self-acupressure

Outcomes

Primary Outcomes

Differences in quality of life during the overall stage

Time Frame: Chemotherapy treatment was initiated to 21 days after the last chemotherapy cycle

Difference in change in EQ-5D-5L scores from first to last assessment between two arms

Secondary Outcomes

  • Differences in quality of life during the overall stage(Chemotherapy treatment was initiated to 21 days after the last chemotherapy cycle)
  • Changes in scores on the five dimensions of the EQ-5D-5L(Chemotherapy treatment was initiated to 21 days after the last chemotherapy cycle)
  • Changes in the dimensions of the FACT-B scale(Chemotherapy treatment was initiated to 21 days after the last chemotherapy cycle)

Study Sites (1)

Loading locations...

Similar Trials